Complementary detection of clinically significant prostate cancer by magnetic resonance imaging fusion-targeted and systematic transrectal ultrasound-guided biopsy: influence of prostate-specific antigen and prostate-specific antigen density in a retrospective paired cohort
6
Issued Date
2026-01-01
Resource Type
ISSN
22878882
eISSN
2287903X
Scopus ID
2-s2.0-105045291097
Journal Title
Prostate International
Rights Holder(s)
SCOPUS
Bibliographic Citation
Prostate International (2026)
Suggested Citation
Visuthikosol T., Viseshsindh W. Complementary detection of clinically significant prostate cancer by magnetic resonance imaging fusion-targeted and systematic transrectal ultrasound-guided biopsy: influence of prostate-specific antigen and prostate-specific antigen density in a retrospective paired cohort. Prostate International (2026). doi:10.1016/j.prnil.2026.06.003 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/118196
Title
Complementary detection of clinically significant prostate cancer by magnetic resonance imaging fusion-targeted and systematic transrectal ultrasound-guided biopsy: influence of prostate-specific antigen and prostate-specific antigen density in a retrospective paired cohort
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background Multiparametric magnetic resonance imaging (MRI)-targeted biopsy has improved prostate cancer detection, yet the relative diagnostic contributions of MRI-fusion-targeted biopsy and systematic transrectal ultrasound-guided (TRUS) biopsy across prostate-specific antigen (PSA) and PSA density (PSAD) levels remain uncertain. We evaluated the incremental detection of clinically significant prostate cancer (csPCa) between these techniques. Methods This retrospective single-center paired cohort study included 376 men with biopsy-proven prostate cancer who underwent both MRI fusion-targeted and 12-core systematic TRUS biopsy in the same session for a Prostate Imaging Reporting and Data System ≥3 lesion. csPCa was defined as International Society of Urological Pathology Grade Group ≥2. Detection was compared overall and across PSA strata (<4, 4–10, 10.01–20, 20.01–50, >50 ng/mL) and PSAD groups (<0.10, 0.10–<0.15, ≥0.15 ng/mL/cc) using exact McNemar testing on discordant pairs. Results Overall prostate cancer detection was similar between MRI fusion-targeted and systematic TRUS biopsy (318/376, 84.6% vs. 316/376, 84.0%; P = 0.927). csPCa was detected in 226/376 patients (60.1%) by MRI fusion-targeted biopsy and 212/376 (56.4%) by systematic biopsy; 60 MRI-only and 46 systematic-only discordant cases were observed ( P = 0.206). MRI fusion-targeted biopsy showed numerically higher csPCa detection across the intermediate PSA range (4–50 ng/mL), with the largest absolute difference of 9.1 percentage points at PSA 20.01–50 ng/mL ( n = 33); no PSA-stratified comparison reached statistical significance. csPCa detection increased with PSAD for both techniques across all three PSAD strata. Conclusion MRI fusion-targeted and systematic TRUS biopsies were complementary for csPCa detection. MRI fusion-targeted biopsy showed a numerical advantage in the intermediate PSA range, while csPCa detection increased with PSA density for both techniques. These findings support risk-stratified interpretation of biopsy yield and do not support routine omission of systematic cores when MRI-fusion-targeted biopsy is performed.